Filters

Term Search
You can select from the dropdown list OR enter your own terms to refine the search.

Last Updated: 10/31/2025

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 239 publications

Updates on Therapy Options in Fit and Unfit Patients with Newly Diagnosed AML.

Updates on Therapy Options in Fit and Unfit Patients with Newly Diagnosed AML.

Journal: Current treatment options in oncology
Published: July 30, 2025

Trial of Enasidenib Maintenance Post Allogeneic Hematopoietic Cell Transplant in Patients With IDH-2 Mutated AML.

Trial of Enasidenib Maintenance Post Allogeneic Hematopoietic Cell Transplant in Patients With IDH-2 Mutated AML.

Journal: Transplantation and cellular therapy
Published: July 28, 2025

An Interpretable Deep Learning and Molecular Docking Framework for Repurposing Existing Drugs as Inhibitors of SARS-CoV-2 Main Protease.

An Interpretable Deep Learning and Molecular Docking Framework for Repurposing Existing Drugs as Inhibitors of SARS-CoV-2 Main Protease.

Journal: Molecules (Basel, Switzerland)
Published: July 01, 2025

Single center experience of IDH inhibitors in recurrent high-grade gliomas.

Single center experience of IDH inhibitors in recurrent high-grade gliomas.

Journal: Journal of neuro-oncology
Published: June 02, 2025

Enasidenib plus venetoclax in patients with IDH2-mutated relapsed or refractory acute myeloid leukaemia or myelodysplastic syndrome (ENAVEN-AML): a multicentre, single-arm, phase 1b/2 trial.

Enasidenib plus venetoclax in patients with IDH2-mutated relapsed or refractory acute myeloid leukaemia or myelodysplastic syndrome (ENAVEN-AML): a multicentre, single-arm, phase 1b/2 trial.

Journal: The Lancet. Haematology
Published: May 23, 2025

Evaluation of the pharmacokinetics of enasidenib in patients with hepatic impairment.

Evaluation of the pharmacokinetics of enasidenib in patients with hepatic impairment.

Journal: Cancer chemotherapy and pharmacology
Published: May 05, 2025

Metabolism and therapy in acute myeloid leukemia with isocitrate dehydrogenase 1/2 mutations

Metabolism and therapy in acute myeloid leukemia with isocitrate dehydrogenase 1/2 mutations

Journal: Medecine sciences : M/S
Published: April 28, 2025

Enasidenib as treatment for AML with IDH2 mutation: multicenter real-life study of the early-access program in Spain.

Enasidenib as treatment for AML with IDH2 mutation: multicenter real-life study of the early-access program in Spain.

Journal: Annals of hematology
Published: April 09, 2025

PDGCL-DTI: Parallel Dual-channel Graph Contrastive Learning for Drug-Target Binding Prediction in Heterogeneous Networks.

PDGCL-DTI: Parallel Dual-channel Graph Contrastive Learning for Drug-Target Binding Prediction in Heterogeneous Networks.

Journal: IEEE journal of biomedical and health informatics
Published: March 03, 2025

Selecting optimal therapy for higher-risk myelodysplastic syndromes: present and future projections.

Selecting optimal therapy for higher-risk myelodysplastic syndromes: present and future projections.

Journal: Expert opinion on pharmacotherapy
Published: February 16, 2025

Synergistic and antagonistic drug interactions are prevalent but not conserved across acute myeloid leukemia cell lines.

Synergistic and antagonistic drug interactions are prevalent but not conserved across acute myeloid leukemia cell lines.

Journal: Scientific reports
Published: February 04, 2025

State of the Art of IDH Inhibitors: Emerging Questions and Perspectives.

State of the Art of IDH Inhibitors: Emerging Questions and Perspectives.

Journal: Anti-cancer agents in medicinal chemistry
Published: January 29, 2025
Showing 1-12 of 239

Last Updated: 10/31/2025